EL PASO, TX--(Marketwired - Dec 15, 2016) - Premier Biomedical, Inc. (
Greetings From The CEO and Staff at Premier Biomedical!
The past year has been a difficult journey, and events during the year have caused us to re-evaluate and adjust our overall business plan. We believe the significant steps taken will result in a much brighter forecast for 2017 and beyond.
Immunotherapy and Biologics.
Pain Management.
Organizational Revisions.
Stock Price Recovery Program.
Forecast.
We thank you for your continued support and wish you and your family a very Merry Christmas and a Happy, Healthy, and Prosperous New Year!
William A. Hartman
President and CEO
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans, focusing on two major areas -- 1) Biologics and Extracorporeal Treatments; and 2) Non-narcotic Pain Management Products. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending patents and provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
William A. Hartman
President and CEO
Premier Biomedical, Inc.
(724) 633-7033
[email protected]
http://www.premierbiomedical.com/
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member